Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported) August 31, 2017
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
9171
Towne Centre Drive, Suite 440, San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR
240.13e-4(c))
|
Item 7.01 – Regulation FD Disclosure: Corporate
Presentation
On
August 31, 2017, the Company provided an update to its corporate
presentation. The presentation will be available on the
Company’s website at www.innovuspharma.com and
filed herewith as Exhibit 99.1.
The
information set forth in this Item 7.01, including Exhibit 99.1, is
being furnished pursuant to Item 7.01 and shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange
Act ”), or otherwise subject to the liabilities
of that Section, and it shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or under the Exchange Act, whether made before or after
the date hereof, except as expressly provided by specific reference
in such a filing.
By
filing this Current Report on Form 8-K and furnishing the
information in this Item 7.01, the Company makes no admission as to
the materiality of Item 7.01 in this report or the presentation
attached hereto as Exhibit 99.1. The information contained in the
presentation is summary information that is intended to be
considered in the context of the Company’s filings with the
SEC and other public announcements that the Company makes, by press
release or otherwise, from time to time. The Company undertakes no
duty or obligation to publicly update or revise the information
contained in this Item, although it may do so from time to time as
its management believes is appropriate. Any such updating may be
made through the filing of other reports or documents with the SEC,
through press releases or through other public
disclosure.
The
Company cautions you that the presentation attached hereto as
Exhibit 99.1 contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act, as amended.
Statements in the presentation that are not purely historical are
forward-looking statements including, but not limited to, the
Company’s ability to execute its business plan, obtain
regulatory approval for products under development, enter into
partnering agreements, realize revenue and pursue growth
opportunities, some of which are outside the control of the
Company. Readers and attendees are cautioned not to
place undue reliance on these forward-looking statements as actual
results could differ materially from the forward-looking statements
contained herein. Attendees are urged to read the risk factors set
forth in the Company’s most recent annual report on Form
10-K, subsequent quarterly reports filed on Form 10-Q and its most
recent SEC filings. Company disclaims any intention to
update this presentation.
Section 9 – Financial Statements and
Exhibits
Item 9.01 Exhibits
|
Exhibit Number
|
Description
|
|
|
Corporate
Presentation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date: August 31,
2017 |
INNOVUS
PHARMACEUTICALS, INC
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/S/
Bassam Damaj
|
|
|
|
|
Bassam
Damaj, CEO
|